Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II Study
Authors:
- David R. SpigelDSDavid R. Spigel
- David M. WaterhouseDWDavid M. Waterhouse
- Steve LaneSLSteve Lane
- Philippe LegennePLPhilippe Legenne
- Kamal BhattKBKamal Bhatt
- 1 July 2013
- journal article
- research article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 14 (4) , 356-363
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential BiomarkerClinical Cancer Research, 2012
- Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patientsLung Cancer, 2012
- Small cell lung cancer: new clinical recommendations and current status of biomarker assessmentEuropean Journal of Cancer, 2011
- Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20Journal of Clinical Oncology, 2007
- Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04–IFCT 00-01Journal of Clinical Oncology, 2007
- Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancerAnnals of Oncology, 2006
- Small Cell Lung Cancer*Chest, 2003
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung CancerJournal of Clinical Oncology, 1999